Piper Sandler Maintains Overweight on Cardiff Oncology, Lowers Price Target to $5
Piper Sandler analyst Joseph Catanzaro maintains Cardiff Oncology (NASDAQ:CRDF) with a Overweight and lowers the price target from $7 to $5.
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
Gainers
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average price of $2.03 - $2.07.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over the last 100 days. The company's market cap stands at $25.0 million.
Cardiff Oncology Announces Plans For A Randomized Trial, Durability Of Responses In Ongoing Phase 1b/2 Trial In Metastatic Colorectal Cancer And Additional Business Updates
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expected in 2H
Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer
Clinical-stage biotech Cardiff Oncology Inc (NASDAQ:CRDF) announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC)…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million.
Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6
Baird analyst Joel Beatty maintains Cardiff Oncology (NASDAQ:CRDF) with a Outperform and lowers the price target from $9 to $6.
Looking Into Cardiff Oncology’s Return On Capital Employed
According to data from Benzinga Pro, during Q2, Cardiff Oncology's (NASDAQ:CRDF) reported sales totaled $91 thousand. Despite a 5.0% increase in earnings, the company posted a loss of $10.44 million.
